Margot Jak

6PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 15, 2026
Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.

|Feb 26, 2024
Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.

Niels van Nieuwenhuijzen, Marta Cuenca, Leonie Abbink

|Nov 25, 2023
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.

Janneke W de Boer, Kylie Keijzer, Elise R A Pennings

|Sep 09, 2023
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.

Anne M Spanjaart, Elise R A Pennings, Pim G N J Mutsaers

|Aug 28, 2023
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.

Janneke W de Boer, Elise R A Pennings, Ankie Kleinjan

|Aug 07, 2018
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.

Rimke Oostvogels, Margot Jak, Reinier Raymakers

Pageof 1

Frequent Collaborators

4 joint publications

Janneke W de Boer

4 joint publications

Elise R A Pennings

4 joint publications

Pim G N J Mutsaers

4 joint publications

Joost S P Vermaat